Related Experiment Video
Updated: Dec 15, 2025
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Can melatonin and its metabolites boost the efficacy of targeted therapy in patients with advanced melanoma?
Konrad Kleszczyński1, Markus Böhm1
1Department of Dermatology, University of Münster, Münster, Germany.
Abstract:
Despite groundbreaking new treatments such as checkpoint inhibition and targeted therapy, the overall response and survival rates are limited in patients with metastatic melanoma. Here, we hypothesize that melatonin and its metabolites could be promising boosters of the efficacy of BRAF/MEK inhibitors in patients with advanced melanoma. Melatonin, a well-known endogenous synchronizer of the circadian biorhythm has a variety of promising effects for melanoma biology. It regulates proliferation, apoptosis and oxidative phosphorylation via melatonin receptors, and receptor-independent pathways due to its lipophilicity. By means of interfering with the above cellular pathways, melatonin and related compounds may alter the cAMP-PKA-MITF axis, modulate tumor cell metabolism, affect MAPK signalling pathway thereby enhancing the suppressive effect of BRAF/MEK inhibitors on melanoma cell growth, and survival. Such findings could fuel preclinical studies and clinical studies where melatonin or its metabolites are combined with targeted therapy to better treat patients with metastatic melanoma.
Insights
Melatonin may enhance BRAF/MEK inhibitors for metastatic melanoma. This research suggests combining melatonin with targeted therapy could improve treatment outcomes for advanced melanoma patients.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Metastatic melanoma treatment response and survival rates remain limited despite advances like checkpoint inhibition and targeted therapy.
- Melatonin, a circadian rhythm regulator, exhibits multifaceted effects on melanoma biology, including regulation of proliferation and apoptosis.
- Melatonin's lipophilicity allows receptor-dependent and independent pathway interactions.
Purpose of the Study:
- To investigate the potential of melatonin and its metabolites as efficacy boosters for BRAF/MEK inhibitors in advanced melanoma.
- To explore the mechanisms by which melatonin may enhance the anti-melanoma effects of targeted therapies.
Main Methods:
- Hypothesizing melatonin's interference with cellular pathways relevant to melanoma growth and survival.
- Considering melatonin's potential modulation of the cAMP-PKA-MITF axis and MAPK signaling pathway.
- Exploring receptor-dependent and independent mechanisms of melatonin action.
Main Results:
- Melatonin may enhance the suppressive effects of BRAF/MEK inhibitors on melanoma cell growth and survival.
- Melatonin's interaction with cellular pathways could potentiate targeted therapy efficacy.
- Potential for melatonin to modulate tumor cell metabolism and MAPK signaling.
Conclusions:
- Melatonin and its metabolites show promise as adjuncts to BRAF/MEK inhibitors in metastatic melanoma.
- Combining melatonin with targeted therapy could improve patient outcomes.
- Further preclinical and clinical studies are warranted to validate these findings.
Related Concept Videos
01:19Management of Insomnia
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy